Association of Matrix Metalloproteinase 3 and 11β-Hydroxysteroid Dehydrogenase Type 1 Gene Polymorphisms with Type 2 Diabetes in Koreans
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Type 2 diabetes is a typical polygenic disease complex, for which several common risk alleles have been identified. Matrix metalloproteinase-3 (MMP3) is an enzyme known to be involved in the destruction of the extracellular matrix in normal physiological processes and disease. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) that catalyzes the conversion of inactive cortisone to active cortisol. is related to the development of type 2 diabetes. Therefore, we investigated the genotypes for the SNP rs522616 in MMP3 gene and rs12086634 in 11β-HSD1 gene between patients and the control group in Korean population. One hundred patients (Male 58, Female 42) with type 2 diabetes (T2D) and 100 controls (Male 36, Female 64) participated in this study. As a result, there was no association between the SNP rs522616 in MMP3 gene, rs12086634 in 11β-HSD1 gene and T2D. Further studies with larger population may be needed for the development of diagnostic methods at the genetic level.
Abstract
Type 2 diabetes is a typical polygenic disease complex, for which several common risk alleles have been identified. Matrix metalloproteinase-3 (MMP3) is an enzyme known to be involved in the destruction of the extracellular matrix in normal physiological processes and disease. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) that catalyzes the conversion of inactive cortisone to active cortisol. is related to the development of type 2 diabetes. Therefore, we investigated the genotypes for the SNP rs522616 in MMP3 gene and rs12086634 in 11β-HSD1 gene between patients and the control group in Korean population. One hundred patients (Male 58, Female 42) with type 2 diabetes (T2D) and 100 controls (Male 36, Female 64) participated in this study. As a result, there was no association between the SNP rs522616 in MMP3 gene, rs12086634 in 11β-HSD1 gene and T2D. Further studies with larger population may be needed for the development of diagnostic methods at the genetic level.
참고문헌 (23)
- Stimvoll M, "Type 2 diabetes; principles of pathogenesis and therapy", Lancet, 365, pp.1333~1346 (2005)
- Grundy SM, "Hypertriglyceridemia, insulin resistance, and the metabolic syndrome", Am J Cardiol, 83, pp.25F~29F (1999)
- Malandrino N, "Personalized medicine in diabetes", Clin Chem, 57(2), pp.231~240 (2011)
- Marchetti P, "From genotype to human beta cell phenotype and beyond", Islets, 4(5), pp.323~332 (2012)
- Scheen AJ, "Type 2 diabetes: journey in the heart of a complex disease", Rev Med Liege, 67(5-6), pp.326~331 (2012)
- Zákovičová E, "Circulating serum matrix metalloproteinase-3 and metalloproteinase-9 are not associated with echocardiographic parameters of diastolic function in asymptomatic type 2 diabetic patients", J Int Med Res, 38(6), pp.2093~2099 (2010)
- Egeblad M, "New functions for the matrix metalloproteinases in cancer progression", Nat Rev Cancer, 2(3), pp.161~174 (2002)
- Henney AM1, "Localization of Stromelysin gene expression in atherosclerotic plaques by in situ hybridization", Prc Natl Acad Sci, 88, pp.8154~8158 (1991)
- Wang H, "Vascular endothelial growth factor upregulatesthe expression of matrix metalloproteinases in vascular smooth muscle cells; role of flt-1", Circ Res, 83, pp.832~840 (1998)
- Ferrara N, "Role of vasclar endothelial growth factor in regulation of physiological angiogenesis", Am J Physiol Cell Physiol, 280, pp.1358~1366 (2001)
- Galis ZS, "Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atheroscleotic plaques", J Clin Invest, 94, pp.2493~2503 (1994)
- Newby AC, "Dual role of matrix metalloproteinases(matrixins)in intimal thickening and atherosclerotic plaque rupture", Physiol Rev, 85, pp.1~31 (2005)
- Pöllänen PJ, "Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3 : the Helsinki Sudden Death Study", Atherosclerosis, 164(2), pp.329~335 (2002)
- Fallah S, "Risk of coronary artery stenosis in Iranian type 2 diabetics : is there a role for matrix metalloproteinase-3 gene(-1612 5A", 6A)polymorphism, 2010, pp.66(4), 359~364
- Zhao Y, "The rs522616polymorphism in the matrix metalloproteinase-3(MMP-3)gene is associated with sporadic brain arteriovenous malformation in a Chinese population", J Clin Neurosci, 17(12), pp.1568~1572 (2010)
- Nair S, "11beta-Hydroxysteroid dehydrogenase Type 1 : genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle", Diabetologia, 47(6), pp.1088~1095 (2004)
- Akiyama N1, "Pharmacological Evaluation of Adipose Dysfunction via 11β-Hydroxysteroid Dehydrogenase Type 1 in the Development of Diabetes in Diet-Induced Obese Mice with Cortisone Pellet Implantation", J Pharmacol Exp Ther, 349(1), pp.66~74 (2014)
- Lee JH, "Regulation of 11β-HSD1 expression during adipose tissue expansion by hypoxia through different activities of NF-κB and HIF-1α", Am J Physiol Endocrinol Metab, 304(10), pp.1035~1041 (2013)
- Schnackenberg CG, "Chronic Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome", Biomed Res Int, 2013, pp.427~436 (2013)
- Chapman K, "11β-Hydroxysteroid Dehydrogenases:Intracellular Gate-Keepers of Tissue Glucocorticoid Action", Physiol Rev, 93(3), pp.1139~1206 (2013)
- Davani B, "Type 1 11beta-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets", J Biol Chem, 275, pp.34841~34844 (2000)
- Duplomb L, "Increased expression and activity of 11beta-HSD-1in diabetic islets and prevention with troglitazone", Biochem Biophys Res Commun, 313, pp.594~599 (2004)
- Koska J, "11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue and prospective changes in body weight and insulin resistance", Obesity, 14(9), pp.1515~1522 (2006)